| scholarly article | Q13442814 |
| P50 | author | Hoon Hur | Q59206744 |
| Han Hong Lee | Q43848356 | ||
| P2093 | author name string | Wook Kim | |
| Ae Ryung Park | |||
| Hae Myung Jeon | |||
| Soo Hong Kim | |||
| P2860 | cites work | Oxaliplatin: available data in non-colorectal gastrointestinal malignancies | Q30666815 |
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients | Q33345474 | ||
| Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer | Q33359580 | ||
| A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients | Q33366008 | ||
| Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC). | Q33372169 | ||
| Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer | Q33379767 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| Chemotherapy of metastatic gastric cancer. | Q33968873 | ||
| Developments in the treatment of gastric cancer in Europe | Q34152660 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| A systematic overview of chemotherapy effects in gastric cancer | Q34301229 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| Chemotherapy for metastatic gastric cancer: past, present, and future | Q37155553 | ||
| Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer | Q37425689 | ||
| Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate | Q41231593 | ||
| Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). | Q43516115 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). | Q46990345 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 18-23 | |
| P577 | publication date | 2010-03-31 | |
| P1433 | published in | Cancer Research and Treatment | Q18411021 |
| P1476 | title | Outcomes of modified FOLFOX-6 as first line treatment in patients with advanced gastric cancer in a single institution; retrospective analysis | |
| P478 | volume | 42 |
| Q33400418 | A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin |
| Q38969972 | Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery |
| Q33609291 | Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer |
| Q35948108 | Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer |
| Q49337286 | Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer |
| Q37142254 | Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer |
| Q37989161 | Management of advanced gastric cancer. |
| Q36536982 | Outcomes of third-line docetaxel-based chemotherapy in advanced gastric cancer who failed previous oxaliplatin-based and irinotecan-based chemotherapies |
| Q33402018 | Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status |
| Q48143725 | Prognostic significance of interim 18 F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer. |
| Q34205672 | Targeted therapies for gastric cancer: current status |
| Q36072532 | The clinical analysis of acute pancreatitis in colorectal cancer patients undergoing chemotherapy after operation |
Search more.